HC Wainwright Reiterates Buy Rating on Unicycive Therapeutics
HC Wainwright maintains its buy rating on Unicycive Therapeutics with a $15 price target, a 211.29% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for Unicycive Therapeutics, setting a price target of $15 on June 30, 2026.
- HC Wainwright's $15 price target implies 211.29% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.82 share price.
- Shares of Unicycive Therapeutics traded near $4.59 on Wednesday, with a market cap of around $128.5 million.
- Insider buying includes CEO Shalabh Gupta acquiring 762,200 shares on May 14, 2026, with no price disclosed.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating on Unicycive Therapeutics, Inc. (NASDAQ: UNC), maintaining a price target of $15. This update came on June 30, 2026, from analyst Swayampakula Ramakanth. Shares of Unicycive traded near $4.59 on Wednesday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Unicycive Therapeutics
Millennium Management LLC increased its holdings in Unicycive by 384,505 shares, bringing its total to 1,399,348 shares worth approximately $9.21 million, marking a 37.9% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 811,430 shares valued at about $5.34 million.
Unicycive Therapeutics, Inc. Stock Down 8.5%
On Wednesday, shares of Unicycive Therapeutics (NASDAQ: UNCY) traded near $4.59. The company has a market cap of approximately $128.5 million and a forward P/E ratio of 0.86. Its beta is 1.726, indicating higher volatility compared to the market. The stock's 52-week range is between $3.71 and $8.74, with a 50-day moving average of $7.56 and a 200-day moving average of $6.25. Unicycive has a current ratio of 2.4 and a quick ratio of 2.06, with a debt-to-equity ratio of 2.16.
$UNCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Unicycive Therapeutics, Inc.
On May 14, 2026, several insiders purchased shares of Unicycive Therapeutics. CEO Shalabh Gupta acquired 762,200 shares, while EVP of Pharmaceuticals and BD, Pramod Gupta, bought 169,500 shares. EVP of Corporate Strategy, Douglas Jermasek, also bought 169,500 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 30, 2026, HC Wainwright & Co. maintained its buy rating on Unicycive Therapeutics with a $15 price target. On the same day, B. Riley Securities also maintained a buy rating, setting a target of $22. Benchmark maintained its buy rating with an $18 target on June 2. The consensus among analysts is a strong buy, with a mean price target of $41.3 based on 10 analyst opinions.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing treatments for kidney diseases. Based in Mountain View, California, and led by CEO Dr. Pramod Gupta, the company is working on oxylanthanum carbonate for hyperphosphatemia in dialysis patients and UNI-494 for acute kidney injury. Founded in 2016, Unicycive is a clinical-stage firm with 21 employees.
Bottom Line
Unicycive Therapeutics remains on the radar of analysts like HC Wainwright, who reaffirmed their buy rating with a $15 target. The company's stock is showing volatility, typical of biotech firms, and is closely watched by investors for its innovative treatments in kidney disease. Keep in mind that analyst ratings and 13F filings provide a snapshot of past positions and sentiment, not necessarily current ones.
Get Unicycive Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UNCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.